Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis
Open Access
- 8 April 2021
- journal article
- research article
- Published by Springer Nature in Diagnostic Pathology
- Vol. 16 (1) , 1-10
Abstract
Background: This study aimed to investigate the association between clinicopathologic factors, mesothelin, and cancer antigen (CA) 125 in endometrial carcinoma. Methods: Between 1989 and 2017, patients with endometrial carcinoma who underwent total hysterectomy and bilateral salpingo-oophorectomy at our hospital were identified. The association between either or both immunochemical expression of mesothelin and CA125 and clinicopathological features were retrospectively examined. Results: Among 485 patients, 171 were positive for mesothelin, 368 were positive for CA125, and 167 were positive for mesothelin and CA125. The expression of mesothelin and CA125 was positively correlated (p < 0.01). More patients with mesothelin expression showed myometrial invasion of more than 50% (p = 0.028) and positive lymphovascular invasion (p = 0.027). Similarly, more patients with co-expression of mesothelin and CA125 had myometrial invasion of more than 50% (p = 0.016) and positive lymphovascular invasion (p = 0.02). Patients with mesothelin expression and co-expression of mesothelin and CA125 demonstrated worse progression-free survival (PFS) and overall survival (OS). In the multivariate analysis, mesothelin expression and co-expression were poor prognostic factors for PFS (mesothelin expression: hazard ratio [HR] = 2.14, p < 0.01; co-expression: HR = 2.19, p < 0.01) and OS (mesothelin expression: HR = 2.18, p < 0.01; co-expression: HR = 2.22, p < 0.01). Conclusions: Mesothelin expression and co-expression might be associated with tumor aggressiveness and poor prognosis in patients with endometrial carcinoma. Persons with mesothelin-expressing endometrial cancers present a particularly high medical unmet need.Keywords
This publication has 36 references indexed in Scilit:
- High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis2019
- Current recommendations and recent progress in endometrial cancerCA: A Cancer Journal for Clinicians, 2019
- Mesothelin expression has prognostic value in stage ΙΙ/ΙΙΙ colorectal cancerVirchows Archiv, 2019
- Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade)International Journal of Gynecological Pathology, 2019
- Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian CancerMolecular Cancer Therapeutics, 2016
- MUC16 (CA125): tumor biomarker to cancer therapy, a work in progressMolecular Cancer, 2014
- Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumorsMolecular Cancer, 2006
- Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous CarcinomaClinical Cancer Research, 2006
- Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.Proceedings of the National Academy of Sciences, 1996
- Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesotheliumInternational Journal of Cancer, 1992